Trials / Active Not Recruiting
Active Not RecruitingNCT03701399
Troriluzole in Adult Participants With Spinocerebellar Ataxia
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Conditions
- Spinocerebellar Ataxias
- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 2
- Spinocerebellar Ataxia Type 3
- Spinocerebellar Ataxia Type 6
- Spinocerebellar Ataxia Type 7
- Spinocerebellar Ataxia Type 8
- Spinocerebellar Ataxia Type 10
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | troriluzole | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2019-03-08
- Primary completion
- 2022-02-18
- Completion
- 2026-06-01
- First posted
- 2018-10-10
- Last updated
- 2025-11-04
- Results posted
- 2025-02-10
Locations
23 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03701399. Inclusion in this directory is not an endorsement.